| Identifier |
20230314_nanos_posters_298 |
| Title |
VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED): Interim Phase 1/2 Pharmacodynamic Results |
| Creator |
Kelly Foster; Brent Dickinson; Rochelle Summerfelt; Angela She; Vahe Bedian; Barrett Katz |
| Affiliation |
(KF) (BD) (RS) (AS) (VB) (BK) Viridian Therapeutics Inc. |
| Subject |
Graves' Disease; Neuro-ophth & Systemic Disease (eg. MS, MG, Thyroid); Orbit/ocular Pathology |
| Description |
VRDN-001, a full antagonist antibody to the insulin-like growth factor-1 receptor (IGF-1R), is under development for the treatment of thyroid eye disease (TED). Clinical and preclinical studies have confirmed IGF-1R antagonism 0reduces the inflammation and proptosis that occur in TED. We provide interim pharmacodynamic (PD) results in healthy volunteers (HVs) and TED patients from our ongoing phase 1/2 clinical trial (NCT05176639) evaluating VRDN-001 dosed at 3-20 mg/kg. |
| Date |
2023-03-14 |
| Language |
eng |
| Format |
application/pdf |
| Type |
Text |
| Source |
2023 North American Neuro-Ophthalmology Society Annual Meeting |
| Relation is Part of |
NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| Collection |
Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu |
| Publisher |
Spencer S. Eccles Health Sciences Library, University of Utah |
| Holding Institution |
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416 |
| Rights Management |
Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
| ARK |
ark:/87278/s6tpwe42 |
| Setname |
ehsl_novel_nam |
| ID |
2335503 |
| Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6tpwe42 |
